Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.

Abstract: Disclosed herein is an aerogel made from a polyhydroxy benzene compound crosslinked with formaldehyde. The aerogel is dry and has a first volume and wherein the aerogel can be exposed to a liquid and be re-dried in a gas while retaining at least 70% of the first volume.

Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.

Abstract: The present disclosure is concerned with benzoannulene compounds that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, chikungunya, Venezuelan equine encephalitis, dengue, influenza, and zika, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed herein is an injection device with housing that defines a channel and a first injection guide opening. The first injection guide opening enters the channel in a manner that allows a needle to penetrate a vessel in an animal with accuracy and at the same time protect the user from the needle.

Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Systems and methods for controlling application of horizontal resistive force to a user walking on a treadmill to provide substantially constant force even if the user changes his or her relative position on the treadmill. The systems and methods can improve the user experience when force is applied while also improving user safety. The system has a cable, a motor, and a system controller. The cable can be coupled to a harness to apply a horizontal resistive force to a treadmill user, and the motor can be coupled to the cable and configured to apply a motor force to the cable. The cable can have an adjustable operative length. The system controller can have a processor communicatively coupled to the motor and configured to adjust the force applied by the motor in response to changes in cable length and a measurement of the actual force applied by the cable.

Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.

Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

Abstract: Disclosed herein is a method and apparatus that uses a brine from a well that is used to both generate electricity and recover valuable minerals present in the brine. The method and apparatus uses a hydrophobic membrane to separate water vapor from the brine to concentrate the brine that is then used to recover the minerals.

Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.

Abstract: A method performed by an ultrasonic inspection system includes delivering to a multilayer structure an ultrasonic pulse that sweeps through a chirp bandwidth, and receiving from the multilayer structure ultrasonic energy including a series of time-overlapping reflections of the pulse delivered to the multilayer structure from layers of the multilayer structure. The method also includes performing frequency domain processing on the ultrasonic energy to produce frequency resonance peaks respectively indicative of distinct layers of the multilayer structure, and performing time domain processing on the ultrasonic energy to compress the time-overlapping reflections into respective time-separated reflection time peaks. The method also includes displaying the frequency resonance peaks on a frequency domain plot, and displaying the reflection time peaks on a time domain plot.

Abstract: An imaging phantom having a housing and a dynamic perfusion assembly positioned within the housing. The dynamic perfusion assembly permits the flow of at least one contrast agent into a non-contrast solution at a desired rate. The dynamic perfusion assembly includes a first chamber that receives at least one contrast agent and a second chamber that receives a non-contrast solution. The second chamber receives the at least one contrast agent from the first chamber at the desired rate.

Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).

Abstract: Disclosed herein is a method useful in the process of contacting a first product that includes ethylene glycol, propylene glycol, and glycerol with the catalyst composition, thereby producing a second product that includes acrolein and acetaldehyde.

Abstract: A thermochemical energy storage system and method of storing thermal energy are disclosed. The energy storing system described herein comprises a reactor comprising a CO2 sorbent comprising i) CaO and mayenite or ii) Li4SiO4, or a combination thereof, and b) a CO2 source, wherein the CO2 source is in fluid communication with the reactor to allow flow of CO2 between the CO2 source and the reactor. Further, methods are disclosed for storing thermal energy through a wide temperature range.

Abstract: Disclosed herein is an aerogel made from a polyhydroxy benzene compound crosslinked with formaldehyde. The aerogel is dry and has a first volume and wherein the aerogel can be exposed to a liquid and be re-dried in a gas while retaining at least 70% of the first volume.